Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/52912
Title: | Outcomes of antiretroviral therapy in children in Asia and Africa: A comparative analysis of the IeDEA pediatric multiregional collaboration |
Authors: | Valeriane Leroy Karen Malateste Helena Rabie Pagakrong Lumbiganon Samuel Ayaya Fatoumata Dicko Mary Ann Davies Azar Kariminia Kara Wools-Kaloustian Edmond Aka Samuel Phiri Linda Aurpibul Constantin Yiannoutsos Haby Signaté-Sy Lynne Mofenson François Dabis |
Authors: | Valeriane Leroy Karen Malateste Helena Rabie Pagakrong Lumbiganon Samuel Ayaya Fatoumata Dicko Mary Ann Davies Azar Kariminia Kara Wools-Kaloustian Edmond Aka Samuel Phiri Linda Aurpibul Constantin Yiannoutsos Haby Signaté-Sy Lynne Mofenson François Dabis |
Keywords: | Medicine |
Issue Date: | 1-Feb-2013 |
Abstract: | BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level. Copyright © 2012 by Lippincott Williams & Wilkins. |
URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872874429&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/52912 |
ISSN: | 10779450 15254135 |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.